You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎医药-SB(09688.HK)香港公开发售获约3.43倍认购 预计9月28日挂牌上市
格隆汇 09-25 08:06

格隆汇 9 月 25日丨再鼎医药-SB(09688.HK)发布公告,公司全球发售1056.405万股股份,其中香港发售股份89.8万股,国际发售股份966.605万股,另有15%超额配股权;最终发售价已确定为每股股份562港元,每手买卖单位50股;预期股份将于2020年9月28日于联交所主板挂牌上市。

香港公开发售项下初步可供认购的香港发售股份合共接获10,349份有效申请,认购合共264.515万股香港发售股份,相当于香港公开发售项下初步可供认购香港发售股份总数约3.43倍。国际发售项下初步提呈发售的发售股份获大幅超额认购,相当于国际发售初步可供认购发售股份总数的约6.9倍。

按发售价每股562港元计算,估计集团将收取全球发售所得款项净额约57.304亿港元(假设超额配股权未获行使)。其中,所得款项净额约46.2%将分配至核心产品(包括约22.2%用于与核心产品相关的研发工作及约24.0%用于提升核心产品的商业化能力);约11.8%用于为进行中及计划临床试验以及管线中其他候选药物(尤其是晚期候选药物)的准备中注册备案拨资;约25.0%用于探索新的全球授权及合作机会并引进具有临床验证的潜在全球同类最佳╱同类首创资产,并与集团当前产品管线形成协同效应及与集团的专业知识保持一致;约7.0%用于持续投资及扩大集团的内部研发产品管线以及在全球招聘及培训高端人才;及约10.0%用于为营运资金及其他一般企业用途拨资。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account